Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients

Completed · Not applicable · Has a placebo group

Conditions studied: Complication of Dialysis, Chronic Kidney Disease, Muscle Loss, End Stage Renal Disease

In brief

The purpose of this study is to examine the effect of 6 months of daily beta-hydroxy beta-methylbutyrate (HMB) supplementation on the physical function and the health of bones, arteries and heart in hemodialysis patients.

Key facts

Study ID

NCT01837238

Run by

University of Illinois at Urbana-Champaign

People needed

41

Starts

2012-11-01

Expected to finish

2016-05-01

Last updated by the study team

2016-10-31

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be receiving hemodialysis treatment.
• Must be willing to be randomized to HMB or placebo for 6 months
• Must receive physician clearance to participate

You may not qualify if…

• Bodyweight > 350 lbs
• Currently taking an HMB supplement or HMB containing products (eg. Ensure)

Where it is running

• University of Illinois — Urbana, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.